Idarucizumab OverviewIdarucizumab (BI 655075), sold under the brand name Praxbind, is a monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran. This drug was developed by Boehringer Ingelheim Pharmaceuticals. A large study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation by dabigatran within minutes. It was FDA approved in October 2015. In the United States the wholes...
Read more Idarucizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Idarucizumab
Recent Idarucizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 2.5g/50ml
Other drugs which contain Idarucizumab or a similar ingredient: (1 result)
- PRAXBIND Idarucizumab